The University of Southampton
University of Southampton Institutional Repository

Sedation and analgesia from prolonged pain and stress during mechanical ventilation in preterm infants: is dexmedetomidine an alternative to current practice?

Sedation and analgesia from prolonged pain and stress during mechanical ventilation in preterm infants: is dexmedetomidine an alternative to current practice?
Sedation and analgesia from prolonged pain and stress during mechanical ventilation in preterm infants: is dexmedetomidine an alternative to current practice?

Mechanical ventilation is an uncomfortable and potentially painful intervention. Opioids, such as morphine and fentanyl, are used for analgesia and sedation but there is uncertainty whether they reduce pain in mechanically ventilated infants. Moreover, there may be short-term and long-term adverse consequences such as respiratory depression leading to prolonged mechanical ventilation and detrimental long-term neurodevelopmental effects. Despite this, opioids are widely used, possibly due to a lack of alternatives.Dexmedetomidine, a highly selective alpha-2-adrenergic agonist with analgesic and sedative effects, currently approved for adults, has come into use in newborn infants. It provides analgesia and simulates natural sleep with maintenance of spontaneous breathing and upper airway tone. Although data on pharmacokinetics-pharmacodynamics in preterm infants are scant, observational studies report that using dexmedetomidine in conjunction with opioids/benzodiazepines or on its own can reduce the cumulative exposure to opioids/benzodiazepines. As it does not cause respiratory depression, dexmedetomidine could enable quicker weaning and extubation. Dexmedetomidine has also been suggested as an adjunct to therapeutic hypothermia in hypoxic ischaemic encephalopathy and others have used it during painful procedures and surgery. Dexmedetomidine infusion can cause bradycardia and hypotension although most report clinically insignificant effects.The increasing number of publications of observational studies and clinical use demonstrates that dexmedetomidine is being used in newborn infants but data on safety and efficacy are scant and not of high quality. Importantly, there are no data on long-term neurodevelopmental impact on preterm or term-born infants. The acceptance of dexmedetomidine in routine clinical practice must be preceded by clinical evidence. We need adequately powered and well-designed randomised controlled trials investigating whether dexmedetomidine alone or with opioids/benzodiazepines in infants on mechanical ventilation reduces the need for opioids/benzodiazepine and improves neurodevelopment at 24 months and later as compared with the use of opioids/benzodiazepines alone.

Analgesia/adverse effects, Analgesics, Opioid/adverse effects, Benzodiazepines/adverse effects, Dexmedetomidine/adverse effects, Humans, Infant, Newborn, Infant, Premature, Pain/drug therapy, Pain Management, Respiration, Artificial/adverse effects, Respiratory Insufficiency/chemically induced
Ojha, Shalini
adc62cc2-df92-446f-8ad2-4c0cf006d689
Abramson, Janine
dba4027c-22a7-4ddb-8cc5-570dee3187d9
Dorling, Jon
e55dcb9a-a798-41a1-8753-9e9ff8aab630
Ojha, Shalini
adc62cc2-df92-446f-8ad2-4c0cf006d689
Abramson, Janine
dba4027c-22a7-4ddb-8cc5-570dee3187d9
Dorling, Jon
e55dcb9a-a798-41a1-8753-9e9ff8aab630

Ojha, Shalini, Abramson, Janine and Dorling, Jon (2022) Sedation and analgesia from prolonged pain and stress during mechanical ventilation in preterm infants: is dexmedetomidine an alternative to current practice? BMJ Paediatrics Open, 6 (1), [e001460]. (doi:10.1136/bmjpo-2022-001460).

Record type: Review

Abstract

Mechanical ventilation is an uncomfortable and potentially painful intervention. Opioids, such as morphine and fentanyl, are used for analgesia and sedation but there is uncertainty whether they reduce pain in mechanically ventilated infants. Moreover, there may be short-term and long-term adverse consequences such as respiratory depression leading to prolonged mechanical ventilation and detrimental long-term neurodevelopmental effects. Despite this, opioids are widely used, possibly due to a lack of alternatives.Dexmedetomidine, a highly selective alpha-2-adrenergic agonist with analgesic and sedative effects, currently approved for adults, has come into use in newborn infants. It provides analgesia and simulates natural sleep with maintenance of spontaneous breathing and upper airway tone. Although data on pharmacokinetics-pharmacodynamics in preterm infants are scant, observational studies report that using dexmedetomidine in conjunction with opioids/benzodiazepines or on its own can reduce the cumulative exposure to opioids/benzodiazepines. As it does not cause respiratory depression, dexmedetomidine could enable quicker weaning and extubation. Dexmedetomidine has also been suggested as an adjunct to therapeutic hypothermia in hypoxic ischaemic encephalopathy and others have used it during painful procedures and surgery. Dexmedetomidine infusion can cause bradycardia and hypotension although most report clinically insignificant effects.The increasing number of publications of observational studies and clinical use demonstrates that dexmedetomidine is being used in newborn infants but data on safety and efficacy are scant and not of high quality. Importantly, there are no data on long-term neurodevelopmental impact on preterm or term-born infants. The acceptance of dexmedetomidine in routine clinical practice must be preceded by clinical evidence. We need adequately powered and well-designed randomised controlled trials investigating whether dexmedetomidine alone or with opioids/benzodiazepines in infants on mechanical ventilation reduces the need for opioids/benzodiazepine and improves neurodevelopment at 24 months and later as compared with the use of opioids/benzodiazepines alone.

Text
e001460.full - Version of Record
Download (323kB)

More information

Accepted/In Press date: 22 April 2022
e-pub ahead of print date: 10 May 2022
Keywords: Analgesia/adverse effects, Analgesics, Opioid/adverse effects, Benzodiazepines/adverse effects, Dexmedetomidine/adverse effects, Humans, Infant, Newborn, Infant, Premature, Pain/drug therapy, Pain Management, Respiration, Artificial/adverse effects, Respiratory Insufficiency/chemically induced

Identifiers

Local EPrints ID: 484991
URI: http://eprints.soton.ac.uk/id/eprint/484991
PURE UUID: 8f51dcb9-d113-43a6-9648-2b0847822615
ORCID for Jon Dorling: ORCID iD orcid.org/0000-0002-1691-3221

Catalogue record

Date deposited: 27 Nov 2023 17:57
Last modified: 18 Mar 2024 04:16

Export record

Altmetrics

Contributors

Author: Shalini Ojha
Author: Janine Abramson
Author: Jon Dorling ORCID iD

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×